C-SCADE8 (Completed)
A cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk
- Medicine
- BI 10773 (empagliflozine)
- Population
- Diabetes mellitus
- Phase
- fase III
- Starting year
- 2012
- More information
- ClinicalTrials.gov